Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Cetuximab Plus Irinotecan in KRAS-Wild Type Colorectal Cancer
NCT01004159Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Sep 2009
- Primary completion
- May 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in colorectal cancer (CRC), sponsored by Roswell Park Comprehensive Cancer Center. Started Sep 2009; status: terminated.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01004159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01004159.